Phase 2 N=118 Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa
Breast Cancer
Primary: Rate of Pathologic Complete Response (pCR) — 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=45 A Study Evaluating Sleep, Stress and Infant Nutrition Using a Chatbot
Preterm Birth · Healthy
Primary: Number of Chats on Sleep, Stress and Infant Nutrition — 131; 125 Chats
Phase 4 N=530 Asthma Control Test Guided Treatment in Chinese Subjects
Asthma
Primary: Percentage of Participants Who Had an ACT Total Score >=20 or an Improvement of More Than 3 Points in ACT During the 24-week Treatment Period — 99.2; 94.3 Percentage of…
Phase 2 N=70 Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer
Breast Cancer
Primary: Percentage of Patients Who Are Progression Free at 6 Months or Later. — 86 percentage of partcipants
N/A N=66 Functional Viability Duck Duck Punch
Rehabilitation · Recovery of Function · Stroke
Primary: Fugl-Meyer Upper Extremity Assessment (FMA-UE) — 0.13; 0.12 Units on a scale
N/A N=56 Refitting Frequent Replacement Lens Wearers Into Clariti 1 Day And 1-Day Acuvue Moist Daily Disposable Spherical Lenses
Myopia
Primary: Lens Handling for Lens Insertion — 9.3; 8.0 units on a scale
Phase 3 N=11 Efficacy & Safety of OPN-375 Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video
Nasal Polyposis
Primary: Change From Visit 1 at End of Study in Bilateral Nasal Polyp Grade Using Endoscopic Video — -0.7 units on a scale
Phase 3 N=80 Pecto-Intercostal Fascial Block for Postoperative Analgesia After Cardiac Surgery
Coronary Artery Disease · Sternal Pain
Primary: Opioid Consumption — 40.8; 49.1 Milligram Morphine Equivalents (MME)
N/A N=528 Substance Use Prevention Campaign for American Indian Youth
Adolescent Substance Use
Primary: Alcohol Initiation — 160; 109 Participants — p=.004
Phase 2 N=56 Trastuzumab in Treating Older Women With Early-Stage Breast Cancer
Breast Cancer
Primary: Percent of Participants Experiencing Cardiac Events at 1 Year — 3.6 percentage of participants
Phase 3 N=25 Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Children With Status Epilepticus (Convulsive) in a Healthcare Setting in Japan
Nervous System Diseases
Primary: Percentage of Participants With Response Rate — 80.0 Percentage of participants
Phase 2 N=27 Investigation of the Gut Microbiota in Regulating Nutrient Absorption in Humans
Obesity
Primary: Stool Calories During OF and UF — 5.8; 8.9 percentage of calorie intake
Phase 1 N=116 Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001)
Solid Tumor
Primary: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Phase 2 N=31 Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelodysplastic Syndrome
Myelodysplastic Syndrome (MDS) With Refractory Anemia (RA) · Severe Aplastic Anemia (SAA)
Primary: Number of Participants Who Engrafted by Day 42 — 30 Participants
Phase 1 N=15 CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)
Carcinoma, Non-Small-Cell Lung
Primary: CS-7017-Related Treatment-Emergent Adverse Events Occurring During the Study of Administration of CS-7017 Combined With Erlotinib in Participants With Metastatic or…